M. DOĞU Et Al. , "Lenalidomide-Based Treatment Results in Patients with Relapsed/Refractory Lymphoma (Excluding Mantle Cell Lymphoma): A Multi-Centre Experience," Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları , vol.5, no.3, pp.61-65, 2021
DOĞU, M. Et Al. 2021. Lenalidomide-Based Treatment Results in Patients with Relapsed/Refractory Lymphoma (Excluding Mantle Cell Lymphoma): A Multi-Centre Experience. Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları , vol.5, no.3 , 61-65.
DOĞU, M., SERİN, İ., GEMİCİ, A., KARIŞMAZ, A., & TURGUT, B., (2021). Lenalidomide-Based Treatment Results in Patients with Relapsed/Refractory Lymphoma (Excluding Mantle Cell Lymphoma): A Multi-Centre Experience. Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları , vol.5, no.3, 61-65.
DOĞU, Mehmet Et Al. "Lenalidomide-Based Treatment Results in Patients with Relapsed/Refractory Lymphoma (Excluding Mantle Cell Lymphoma): A Multi-Centre Experience," Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları , vol.5, no.3, 61-65, 2021
DOĞU, Mehmet Et Al. "Lenalidomide-Based Treatment Results in Patients with Relapsed/Refractory Lymphoma (Excluding Mantle Cell Lymphoma): A Multi-Centre Experience." Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları , vol.5, no.3, pp.61-65, 2021
DOĞU, M. Et Al. (2021) . "Lenalidomide-Based Treatment Results in Patients with Relapsed/Refractory Lymphoma (Excluding Mantle Cell Lymphoma): A Multi-Centre Experience." Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları , vol.5, no.3, pp.61-65.
@article{article, author={Mehmet DOĞU Et Al. }, title={Lenalidomide-Based Treatment Results in Patients with Relapsed/Refractory Lymphoma (Excluding Mantle Cell Lymphoma): A Multi-Centre Experience}, journal={Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları}, year=2021, pages={61-65} }